Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins

BackgroundDespite being a mainstay for treating superficial bladder carcinoma and a promising agent for interstitial cystitis, the precise mechanism of Bacillus Calmette-Guerin (BCG) remains poorly understood. It is particularly unclear whether BCG is capable of altering gene expression beyond its well-recognized pro-inflammatory effects and how this relates to its therapeutic efficacy. The objective of this study was to determine differentially expressed genes in the mouse bladder following repeated intravesical BCG therapy.MethodsMice were transurethrally instilled with BCG or pyrogen-free on days 1, 7, 14, and 21. Seven days after the last instillation, urothelia along with the submucosa was removed and amplified ds-DNA was prepared from control- and BCG-treated bladder mucosa and used to generate suppression subtractive hybridization (SSH). Plasmids from control- and BCG-specific differentially expressed clones and confirmed by Virtual Northern were then purified and the inserts were sequenced and annotated. Finally, chromatin immune precipitation combined with real-time polymerase chain reaction assay (ChIP/Q-PCR) was used to validate SSH-selected transcripts.ResultsRepeated intravesical BCG treatment induced an up regulation of genes associated with antigen presentation (B2M, HLA-A, HLA-DQA1, HLA-DQB2, HLA-E, HLA-G, IGHG, and IGH) and representatives of two IFNγ-induced small GTPase families: the GBPs (GBP1, GBP2, and GBP5) and the p47GTPases (IIGTP1, IIGTP2, and TGTP). Genes expressed in saline-treated bladders but down-regulated by BCG included: the single-spanning uroplakins (UPK3a and UPK2), SPRR2G, GSTM5, and RSP 19.ConclusionHere we introduced a hypothesis-generator approach to determine key genes involved in the urothelium/sumbmucosa responses to BCG therapy. Urinary bladder responds to repeated BCG treatment by up-regulating not only antigen presentation-related genes, but also GBP and p47 small GTPases, both potentially serving to mount a resistance to the replication of the Mycobacterium. It will be of tremendous future interest to determine whether these immune response cascades play a role in the anti-cancer effects exerted by BCG.

[1]  W. See,et al.  Autocrine over expression of fibronectin by human transitional carcinoma cells impairs bacillus Calmette-Guerin adherence and signaling. , 2004, The Journal of urology.

[2]  P. Veranič,et al.  What determines differentiation of urothelial umbrella cells? , 2004, European journal of cell biology.

[3]  A. Diokno,et al.  Preliminary study on urinary cytokine levels in interstitial cystitis: does intravesical bacille Calmette-Guérin treat interstitial cystitis by altering the immune profile in the bladder? , 1999, Urology.

[4]  M. Stürzl,et al.  Human guanylate binding protein-1 (hGBP-1) characterizes and establishes a non-angiogenic endothelial cell activation phenotype in inflammatory diseases. , 2005, Advances in enzyme regulation.

[5]  R. Connor,et al.  Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer. , 2007, Cytokine & growth factor reviews.

[6]  E. Kremmer,et al.  The helical domain of GBP‐1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines , 2001, The EMBO journal.

[7]  L. Fiette,et al.  Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes. , 2005, Blood.

[8]  J. Zerrahn,et al.  Disruption of Toxoplasma gondii Parasitophorous Vacuoles by the Mouse p47-Resistance GTPases , 2005, PLoS pathogens.

[9]  A. Sher,et al.  p47 GTPases: regulators of immunity to intracellular pathogens , 2004, Nature Reviews Immunology.

[10]  K. Kurth,et al.  Role of urothelial cells in BCG immunotherapy for superficial bladder cancer , 2004, British Journal of Cancer.

[11]  D. Lamm,et al.  Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials. , 1991, Urology.

[12]  A. Albini,et al.  The guanylate binding protein‐1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP‐1 expression , 2003, The EMBO journal.

[13]  S. Martens,et al.  The interferon-inducible GTPases. , 2006, Annual review of cell and developmental biology.

[14]  M. O'Donnell.  Entrez into the immunogenetics of superficial bladder cancer response to bacillus Calmette-Guerin. , 2006, The Journal of urology.

[15]  H. Whittle,et al.  Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. , 1998, The New England journal of medicine.

[16]  T. Thamboo,et al.  Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon‐alpha , 2007, Cancer.

[17]  J. Chin,et al.  Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor. , 1997, The Journal of urology.

[18]  R. Glockshuber,et al.  Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. , 2001, Journal of cell science.

[19]  B. Davies,et al.  Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy , 2003, British Journal of Cancer.

[20]  J. Mckinney,et al.  Immune control of tuberculosis by IFN-gamma-inducible LRG-47. , 2003, Science.

[21]  R. DeSalle,et al.  Origin of the tetraspanin uroplakins and their co-evolution with associated proteins: implications for uroplakin structure and function. , 2006, Molecular phylogenetics and evolution.

[22]  K. Pfeffer,et al.  Two families of GTPases dominate the complex cellular response to IFN-gamma. , 1998, Journal of immunology.

[23]  Brian J. Smith,et al.  Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. , 2006, Urologic oncology.

[24]  R. Vadigepalli,et al.  The inflammatory and normal transcriptome of mouse bladder detrusor and mucosa , 2006, BMC Physiology.

[25]  E. Wolf,et al.  Mechanisms Regulating the Positioning of Mouse p47 Resistance GTPases LRG-47 and IIGP1 on Cellular Membranes: Retargeting to Plasma Membrane Induced by Phagocytosis1 , 2004, The Journal of Immunology.

[26]  M. Saban,et al.  Gene expression profiling of inflammatory bladder disorders , 2003, Expert review of molecular diagnostics.

[27]  K. Lindpaintner,et al.  Efficacy of SSH PCR in isolating differentially expressed genes , 2002, BMC Genomics.

[28]  F. Garrido,et al.  Different mechanisms can lead to the same altered HLA class I phenotype in tumors. , 2007, Tissue antigens.

[29]  Y. Luo,et al.  Dose‐dependent synergy of Th1‐stimulating cytokines on bacille Calmette–Guérin‐induced interferon‐γ production by human mononuclear cells , 2007, Clinical and experimental immunology.

[30]  Yan Hu,et al.  Murine GBP-5, a new member of the murine guanylate-binding protein family, is coordinately regulated with other GBPs in vivo and in vitro. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[31]  O. Haller,et al.  Interferon-induced Mx protein: a mediator of cellular resistance to influenza virus. , 1987, Interferon.

[32]  K. Knutson,et al.  Tumor antigen-specific T helper cells in cancer immunity and immunotherapy , 2005, Cancer Immunology, Immunotherapy.

[33]  L. Koch,et al.  Gene expression profiling of the left ventricles in a rat model of intrinsic aerobic running capacity. , 2005, Physiological genomics.

[34]  D. Mitropoulos.  Novel insights into the mechanism of action of intravesical immunomodulators. , 2005, In vivo.

[35]  S. Akira,et al.  Adjuvant-Mediated Tumor Regression and Tumor-Specific Cytotoxic Response Are Impaired in MyD88-Deficient Mice , 2004, Cancer Research.

[36]  E. Carosella,et al.  Expression of HLA-G in cancer bladder. , 2005, The Egyptian journal of immunology.

[37]  R. Dantzer,et al.  Bacille Calmette-Guérin inoculation induces chronic activation of peripheral and brain indoleamine 2,3-dioxygenase in mice. , 2005, The Journal of infectious diseases.

[38]  N. Knowlton,et al.  Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG) , 2007, BMC Immunology.

[39]  S. Nakae,et al.  IL-17-Mediated Regulation of Innate and Acquired Immune Response against Pulmonary Mycobacterium bovis Bacille Calmette-Guérin Infection1 , 2007, The Journal of Immunology.

[40]  T. Sun,et al.  Distinct Glycan Structures of Uroplakins Ia and Ib , 2006, Journal of Biological Chemistry.

[41]  K. Rock,et al.  Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. , 2006, Current opinion in immunology.

[42]  P. Gros,et al.  Natural resistance to intracellular infections: Nramp1 encodes a membrane phosphoglycoprotein absent in macrophages from susceptible (Nramp1 D169) mouse strains. , 1996, Journal of immunology.

[43]  S. Kaufmann,et al.  IIGP, a member of the IFN inducible and microbial defense mediating 47 kDa GTPase family, interacts with the microtubule binding protein hook3 , 2004, Journal of Cell Science.

[44]  J. Pak,et al.  Tamm-Horsfall Protein Binds to Type 1 Fimbriated Escherichia coli and Prevents E. coli from Binding to Uroplakin Ia and Ib Receptors* , 2001, The Journal of Biological Chemistry.

[45]  F. Garrido,et al.  Coordinated downregulation of the antigen presentation machinery and HLA class I/β2‐microglobulin complex is responsible for HLA‐ABC loss in bladder cancer , 2005, International journal of cancer.

[46]  N. Sato,et al.  Effect of Human Leukocyte Antigen Class I Expression of Tumor Cells on Outcome of Intravesical Instillation of Bacillus Calmette-Guerin Immunotherapy for Bladder Cancer , 2006, Clinical Cancer Research.

[47]  L. Lacombe,et al.  Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. , 2006, The Journal of urology.

[48]  P. Karakiewicz,et al.  Treatment of BCG failures with intravesical BCG/Interferon: the University of Montreal experience. , 2006, The Canadian journal of urology.

[49]  T. Sun,et al.  In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[50]  John D. Storey,et al.  A network-based analysis of systemic inflammation in humans , 2005, Nature.

[51]  I. Dozmorov,et al.  Transcription factor network downstream of protease activated receptors (PARs) modulating mouse bladder inflammation , 2007, BMC Immunology.

[52]  Grossman Hb.  Superficial bladder cancer: decreasing the risk of recurrence. , 1996, Oncology.

[53]  M. D'Andrea,et al.  Regulatory network of inflammation downstream of proteinase-activated receptors , 2007, BMC Physiology.

[54]  Bert W O'Malley,et al.  Identification of target genes in breast cancer cells directly regulated by the SRC-3/AIB1 coactivator. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[55]  M. O'Donnell,et al.  BCG immunotherapy of bladder cancer: 20 years on , 1999, The Lancet.

[56]  S. Sad,et al.  A Reduced Antigen Load In Vivo, Rather Than Weak Inflammation, Causes a Substantial Delay in CD8+ T Cell Priming against Mycobacterium bovis (Bacillus Calmette-Guérin)1 , 2007, The Journal of Immunology.

[57]  Olivier Lantz,et al.  CD4 cells can be more efficient at tumor rejection than CD8 cells. , 2007 .

[58]  T. Hammond,et al.  Gene expression profiling of mouse bladder inflammatory responses to LPS, substance P, and antigen-stimulation. , 2002, The American journal of pathology.

[59]  Aaron P. Campbell,et al.  Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[60]  D. Dunn,et al.  The interferon-inducible p47 (IRG) GTPases in vertebrates: loss of the cell autonomous resistance mechanism in the human lineage , 2005, Genome Biology.

[61]  A. Segal,et al.  How neutrophils kill microbes. , 2005, Annual review of immunology.

[62]  T. Hammond,et al.  Time course of LPS-induced gene expression in a mouse model of genitourinary inflammation. , 2001, Physiological genomics.

[63]  T. Sun,et al.  Assembly of urothelial plaques: tetraspanin function in membrane protein trafficking. , 2005, Molecular biology of the cell.

[64]  Huben Rp.  Intravesical chemotherapy versus immunotherapy for superficial bladder cancer. , 1996 .

[65]  F. Garrido,et al.  LOH at 6p21.3 region and HLA class altered phenotypes in bladder carcinomas , 2006, Immunogenetics.

[66]  T. Reijke,et al.  BCG treatment and the importance of an inflammatory response , 2004, Urological Research.

[67]  A. Iwasaki,et al.  Toll-like receptor control of the adaptive immune responses , 2004, Nature Immunology.

[68]  F. Garrido,et al.  HLA class I expression in bladder carcinomas. , 2003, Tissue antigens.

[69]  Gregory A. Taylor,et al.  Immune Control of Tuberculosis by IFN-γ-Inducible LRG-47 , 2003, Science.